References
- Ali Khan A, Mudassir J, Mohtar N, Darwis Y. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomedicine. 2013;8:2733–2744. doi: 10.2147/IJN.S41521.
- Bhalekar MR, Pokale R, Bandivadekar M, Madgulkar A, Nagore P. Self Micro-Emulsifying Drug Delivery System for Lymphatic Uptake of Darunavir. J Drug Discov Develop Deliv. 2016;3:1–7.
- Bunaciu AA, Udriştioiu EG, Aboul-Enein HY. X-Ray Diffraction: Instrumentation and Applications. Crit Rev Anal Chem. 2015;45:289–299. doi: 10.1080/10408347.2014.949616.
- Bunjes H, Unruh T. Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Adv Drug Deliv Rev. 2007;59:379–402. doi: 10.1016/j.addr.2007.04.013.
- Casteleyn C, Doom M, Lambrechts E, Van den Broeck W, Simoens P, Cornillie P. Locations of gut-associated lymphoid tissue in the 3-month-old chicken: a review. Avian Pathol. 2010;39:143–150. doi: 10.1080/03079451003786105.
- Cavaco MC, Pereira C, Kreutzer B, et al. Evading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles. Eur J Pharm Biopharm. 2017;110:76–84. doi: 10.1016/j.ejpb.2016.10.024.
- Chiu MH, Prenner EJ. Differential scanning calorimetry: An invaluable tool for a detailed thermodynamic characterization of macromolecules and their interactions. J Pharm Bioallied Sci. 2011;3:39–59. doi: 10.4103/0975-7406.76463.
- Daswadkar SC, Atole AV. Formulation and Evaluation of Solid Lipid Nanoparticles of Olanzapine for the Treatment of Psychosis. J Drug Deliv Ther. 2020;10:25–3. doi: 10.22270/jddt.v10i5-s.4440.
- Dening TJ, Rao S, Thomas N, Prestidge CA. Oral nanomedicine approaches for the treatment of psychiatric illnesses. J Control Release. 2016;223:137–156. doi: 10.1016/j.jconrel.2015.12.047.
- Joseph E, Reddi S, Rinwa V, Balwani G, Saha R. Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects. Eur J Pharm Sci. 2017;104:315–325. doi: 10.1016/j.ejps.2017.03.050.
- Freitas MR, Rolim LA, Soares MF, Rolim-Neto PJ, Albuquerque MM, Soares-Sobrinho JL. Inclusion complex of methyl-β-cyclodextrin and olanzapine as potential drug delivery system for schizophrenia. Carbohydr Polym. 2012;89:1095–1100. doi: 10.1016/j.carbpol.2012.03.072.
- Gershkovich P, Hoffman A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur J Pharm Sci. 2005;26:394–404. doi: 10.1016/j.ejps.2005.07.011.
- Gupta H, Bhandari D, Sharma A. Recent trends in oral drug delivery: a review. Recent Pat Drug Deliv Formul. 2009;3:162–173. doi: 10.2174/187221109788452267.
- Heera P. Shanmugam S. Nanoparticle Characterization and Application : An Overview. Int. J Curr Microbiol App Sci. 2015;4:379–386.
- Hirlekar R, Patil E, Bhairy S. Solid nanostructured lipid carriers loaded with silymarin for oral delivery: Formulation development and evaluation. Curr Trends Pharm Pharm Chem. 2021;3:56–67. doi: 10.18231/j.ctppc.2021.014.
- Jawahar N, Meyyanathan SN, Senthil V, Gowthamarajan K, Elango K. Studies on physico-chemical and pharmacokinetic properties of olanzapine through nanosuspension. J Pharm Sci Res. 2013;5:196–202.
- Jenning V, Gohla S. Comparison of wax and glyceride solid lipid nanoparticles (SLN). Int J Pharm. 2000;196:219–222. doi: 10.1016/S0378-5173(99)00426-3.
- Kalepu S, Manthina M, Padavala V. Oral lipid-based drug delivery systems – an overview. Acta Pharm Sin B. 2013;3:361–372. doi: 10.1016/j.apsb.2013.10.001.
- Kaur CD, Nahar M, Jain NK. Lymphatic targeting of zidovudine using surface-engineered liposomes. J Drug Target. 2008;16:798–805. doi: 10.1080/10611860802475688.
- Koteshwara KB, Reddy MS, Naha A, Nampoothiri M. Nanosuspensions: A novel drug delivery approach. Int J Res Ayurveda Pharm. 2011;2:162–165.
- Liversidge G, Jenkins S, Liversidge EM. Injectable nanoparticulate olanzapine formulations. U.S. Patent No. US20050274887. November 16, 2005.
- Maheswarappa MK, Desai PD. Design and in-vitro evaluation of mouth dissolving tablets of olanzapine. Asian J Pharm. 2011;5:107–113. doi: 10.4103/0973-8398.84551.
- Makwana V, Jain R, Patel K, Nivsarkar M, Joshi A. Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach. Int J Pharm. 2015;495:439–446. doi: 10.1016/j.ijpharm.2015.09.014.
- Millan MJ, Fone K, Steckler T, Horan WP. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014;24:645–692. doi: 10.1016/j.euroneuro.2014.03.008.
- Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161–177. doi: 10.1016/s0939-6411(00)00087-4.
- Natarajan J, Baskaran M, Humtsoe LC, Vadivelan R, Justin A. Enhanced brain targeting efficacy of Olanzapine through solid lipid nanoparticles. Artif Cells Nanomed Biotechnol. 2017;45:364–371. doi: 10.3109/21691401.2016.1160402.
- Patel S, Shah J, Bhairy S, Hirlekar R. Development of Curcumin loaded Nanostructured Lipid Carriers: Preparation, Characterization and Invitro Evaluation of Anti-cancer Activity Against A-549 Human Lung Cancer Cell Line. J Cancer Tumor Int. 2021;11:66–88. doi: 10.9734/JCTI/2021/v11i430162.
- Reddy RN, Shariff A. Solid lipid Nanoparticles: An advanced drug delivery system. Int J Pharm Sci Res. 2013;4:161–171. doi: 10.13040/IJPSR.0975-8232.4(1).161-71.
- Sarraguça MC, Cruz AV, Soares SO, Amaral HR, Costa PC, Lopes JA. Determination of flow properties of pharmaceutical powders by near infrared spectroscopy. J Pharm Biomed Anal. 2010;52:484–492. doi: 10.1016/j.jpba.2010.01.038.
- Shah J, Patel S, Bhairy S, Hirlekar R. Formulation optimization, characterization and in-vitro anti-cancer activity of curcumin loaded nanostructured lipid carriers. Int. J. Curr. Pharm. Res. 2022;14:31–43. doi: 10.22159/ijcpr.2022v14i1.44110.
- Shahhet L, Al-Raghban A, Chehna MF. Improvement of the physicochemical properties of amoxicillin trihydrate powder by recrystallization at different pH values. Int J Pharm Pharm Sci. 2011;3:92–100.
- Sumeet S, Natarajan J, Kunal J, Kuppusamy G, Subramania NM. Olanzapine loaded cationic solid lipid nanoparticles for improved oral bioavailability. Curr Nanosci. 2013;9:26–34. doi: 10.2174/1573413711309010007.
- Wang JS, Taylor R, Ruan Y, Donovan JL, Markowitz JS, Lindsay De Vane C. Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacology. 2004;29:551–557. doi: 10.1038/sj.npp.1300372.